These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 30501012)

  • 61. Clinical-pathological correlations in three patients with fibrodysplasia ossificans progressiva.
    Wentworth KL; Bigay K; Chan TV; Ho JP; Morales BM; Connor J; Brooks E; Shahriar Salamat M; Sanchez HC; Wool G; Pignolo RJ; Kaplan FS; Hsiao EC
    Bone; 2018 Apr; 109():104-110. PubMed ID: 29033382
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent.
    Sinha S; Uchibe K; Usami Y; Pacifici M; Iwamoto M
    Bone; 2016 Sep; 90():59-68. PubMed ID: 26891836
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Elevated plasma RANTES in fibrodysplasia ossificans progressiva - A novel therapeutic target?
    Grgurević L; Novak R; Trkulja V; Hamzić LF; Hrkač S; Grazio S; Santini M
    Med Hypotheses; 2019 Oct; 131():109313. PubMed ID: 31443758
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Joint-specific risk of impaired function in fibrodysplasia ossificans progressiva (FOP).
    Pignolo RJ; Durbin-Johnson BP; Rocke DM; Kaplan FS
    Bone; 2018 Apr; 109():124-133. PubMed ID: 28627475
    [TBL] [Abstract][Full Text] [Related]  

  • 65. ALK2: A Therapeutic Target for Fibrodysplasia Ossificans Progressiva and Diffuse Intrinsic Pontine Glioma.
    Sekimata K; Sato T; Sakai N
    Chem Pharm Bull (Tokyo); 2020; 68(3):194-200. PubMed ID: 32115526
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Activin-A Induces Fewer, but Larger Osteoclasts From Monocytes in Both Healthy Controls and Fibrodysplasia Ossificans Progressiva Patients.
    Schoenmaker T; Botman E; Sariyildiz M; Micha D; Netelenbos C; Bravenboer N; Kelder A; Eekhoff EMW; De Vries TJ
    Front Endocrinol (Lausanne); 2020; 11():501. PubMed ID: 32760351
    [TBL] [Abstract][Full Text] [Related]  

  • 67. ACVR1 (587T>C) mutation in a variant form of fibrodysplasia ossificans progressiva: second report.
    Nakahara Y; Katagiri T; Ogata N; Haga N
    Am J Med Genet A; 2014 Jan; 164A(1):220-4. PubMed ID: 24259422
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Identification of progenitor cells that contribute to heterotopic skeletogenesis.
    Lounev VY; Ramachandran R; Wosczyna MN; Yamamoto M; Maidment AD; Shore EM; Glaser DL; Goldhamer DJ; Kaplan FS
    J Bone Joint Surg Am; 2009 Mar; 91(3):652-63. PubMed ID: 19255227
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Fibrodysplasia ossificans progressiva and osteoimmunology].
    Katagiri T
    Clin Calcium; 2016 May; 26(5):691-8. PubMed ID: 27117614
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Analog Method for Radiographic Assessment of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva.
    Rajapakse CS; Lindborg C; Wang H; Newman BT; Kobe EA; Chang G; Shore EM; Kaplan FS; Pignolo RJ
    Acad Radiol; 2017 Mar; 24(3):321-327. PubMed ID: 27989444
    [TBL] [Abstract][Full Text] [Related]  

  • 71. ACVR1 Function in Health and Disease.
    Valer JA; Sánchez-de-Diego C; Pimenta-Lopes C; Rosa JL; Ventura F
    Cells; 2019 Oct; 8(11):. PubMed ID: 31683698
    [No Abstract]   [Full Text] [Related]  

  • 72. A Door Opens for Fibrodysplasia Ossificans Progressiva.
    Katagiri T
    Trends Biochem Sci; 2016 Feb; 41(2):119-121. PubMed ID: 26654278
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Application of human induced pluripotent stem cells to model fibrodysplasia ossificans progressiva.
    Barruet E; Hsiao EC
    Bone; 2018 Apr; 109():162-167. PubMed ID: 28716551
    [TBL] [Abstract][Full Text] [Related]  

  • 74. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
    Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN
    Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Oxidative phosphorylation is a pivotal therapeutic target of fibrodysplasia ossificans progressiva.
    Sun L; Jin Y; Nishio M; Watanabe M; Kamakura T; Nagata S; Fukuda M; Maekawa H; Kawai S; Yamamoto T; Toguchida J
    Life Sci Alliance; 2024 May; 7(5):. PubMed ID: 38365425
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP).
    Shore EM; Kaplan FS
    Bone; 2008 Sep; 43(3):427-33. PubMed ID: 18590993
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Induced Pluripotent Stem Cells to Model Human Fibrodysplasia Ossificans Progressiva.
    Cai J; Orlova VV; Cai X; Eekhoff EMW; Zhang K; Pei D; Pan G; Mummery CL; Ten Dijke P
    Stem Cell Reports; 2015 Dec; 5(6):963-970. PubMed ID: 26626181
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva.
    Katagiri T; Tsukamoto S; Kuratani M
    Bone; 2018 Apr; 109():241-250. PubMed ID: 28754575
    [TBL] [Abstract][Full Text] [Related]  

  • 79. An Adult Zebrafish Model of Fibrodysplasia Ossificans Progressiva.
    LaBonty M; Yelick PC
    Methods Mol Biol; 2019; 1891():155-163. PubMed ID: 30414131
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling.
    Wang H; Lindborg C; Lounev V; Kim JH; McCarrick-Walmsley R; Xu M; Mangiavini L; Groppe JC; Shore EM; Schipani E; Kaplan FS; Pignolo RJ
    J Bone Miner Res; 2016 Sep; 31(9):1652-65. PubMed ID: 27027798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.